FDA approves Aloxi for treatment of chemotherapy-related nausea/vomiting in children
- FDA approved Esai’s Aloxi for prevention of chemotherapy-induced nausea and vomiting (CINV) in children.
- Indication covers children between the ages of one month and 17 years.
- Aloxi is the first drug approved for treatment of acute CINV in infants between ages one month and six months.
Aloxi was compared with the standard of care, odansetron, and was deemed non-inferior (59.4% of Aloxi-treated patients had a complete response versus 58.6% of odansetron-treated patients). However, while odansetron requires an initial infusion, followed by two follow-ups, Aloxi requires one infusion based on treatment guidelines.